Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DHR 
Danaher Corporation (DHR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: DHR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $247.57
1 Year Target Price $247.57
| 19 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 142.28B USD | Price to earnings Ratio 38.45 | 1Y Target Price 247.57 |
Price to earnings Ratio 38.45 | 1Y Target Price 247.57 | ||
Volume (30-day avg) 26 | Beta 0.8 | 52 Weeks Range 170.73 - 280.22 | Updated Date 06/30/2025 |
52 Weeks Range 170.73 - 280.22 | Updated Date 06/30/2025 | ||
Dividends yield (FY) 0.64% | Basic EPS (TTM) 5.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.81% | Operating Margin (TTM) 22.49% |
Management Effectiveness
Return on Assets (TTM) 3.93% | Return on Equity (TTM) 7.22% |
Valuation
Trailing PE 38.45 | Forward PE 26.39 | Enterprise Value 156759115287 | Price to Sales(TTM) 5.97 |
Enterprise Value 156759115287 | Price to Sales(TTM) 5.97 | ||
Enterprise Value to Revenue 6.58 | Enterprise Value to EBITDA 21.94 | Shares Outstanding 715670016 | Shares Floating 636731238 |
Shares Outstanding 715670016 | Shares Floating 636731238 | ||
Percent Insiders 11.04 | Percent Institutions 82.47 |
Analyst Ratings
Rating 5 | Target Price 247.57 | Buy 4 | Strong Buy 19 |
Buy 4 | Strong Buy 19 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Danaher Corporation
Company Overview
History and Background
Danaher Corporation was founded in 1969 as DMG, Inc., a real estate investment trust. It transformed into a manufacturing company in the 1980s and adopted the Danaher name in 1984. Through strategic acquisitions and a focus on continuous improvement via the Danaher Business System (DBS), it has evolved into a global science and technology innovator.
Core Business Areas
- Life Sciences: Provides a broad range of research tools to study basic biology, understand disease, and develop new therapies.
- Diagnostics: Offers instruments, reagents, consumables, software and services that are used to diagnose disease and guide treatment decisions.
- Environmental & Applied Solutions: Provides solutions that help protect critical resources and keep the worldu2019s food and water safe. This includes water quality and product identification solutions.
Leadership and Structure
Rainer M. Blair is the current President and CEO. Danaher operates with a decentralized organizational structure, empowering its operating companies while adhering to the DBS principles.
Top Products and Market Share
Key Offerings
- Cytiva Bioprocess: Cytiva provides technologies and services for cell and gene therapy, antibody production, and vaccine development. It holds a significant market share in bioprocessing solutions. Competitors include Thermo Fisher Scientific and Sartorius.
- Market Share (%): 20
- Beckman Coulter Diagnostics: Beckman Coulter Diagnostics offers clinical diagnostics instruments and reagents used in hospitals and labs. Market share varies by segment but is a major player. Competitors include Roche, Abbott, and Siemens Healthineers.
- Market Share (%): 10
- Hach Water Quality Solutions: Hach provides instruments and reagents for water quality analysis in municipal, industrial, and environmental settings. Holds a leading position in many segments. Competitors include Xylem and Endress+Hauser.
- Market Share (%): 15
- Leica Microsystems: Leica Microsystems provides microscope and scientific instruments. Competitors include Zeiss and Nikon.
- Market Share (%): 18
Market Dynamics
Industry Overview
The life sciences, diagnostics, and environmental & applied solutions industries are experiencing growth due to factors such as increasing healthcare spending, aging populations, and growing concerns about environmental sustainability.
Positioning
Danaher is positioned as a premium provider of high-tech solutions with a strong brand reputation, driven by its focus on innovation and operational excellence through the Danaher Business System.
Total Addressable Market (TAM)
Estimated at several hundreds of billions of dollars across its various segments. Danaher is well-positioned to capitalize on this large TAM through organic growth, acquisitions, and innovation.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Danaher Business System (DBS)
- Decentralized operating model
- Proven track record of acquisitions
- Diverse product portfolio
Weaknesses
- Reliance on acquisitions for growth
- Exposure to cyclical industries
- Integration risks from acquisitions
- High debt levels
Opportunities
- Growing demand for healthcare and environmental solutions
- Expansion into emerging markets
- Technological advancements in genomics and diagnostics
- Acquisitions of complementary businesses
Threats
- Economic downturns
- Increased competition
- Regulatory changes
- Disruptive technologies
Competitors and Market Share
Key Competitors
- TMO
- ROSY
- ABT
- SIEMENS-HEALTHINEERS.NS
Competitive Landscape
Danaher's competitive advantages include its strong brand, DBS, and diverse product portfolio. Disadvantages may include high debt levels and reliance on acquisitions.
Major Acquisitions
Abcam
- Year: 2023
- Acquisition Price (USD millions): 5700
- Strategic Rationale: Expands Danaher's presence in the life sciences market and adds a complementary product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historically, Danaher has grown through a combination of organic growth, margin expansion, and strategic acquisitions.
Future Projections: Analysts project continued growth in revenue and earnings, driven by its strong market position and the growing demand for its products and services.
Recent Initiatives: Recent initiatives include strategic acquisitions in key growth areas and investments in research and development.
Summary
Danaher Corporation is a strong, diversified science and technology company, with a proven track record of growth through acquisitions and organic initiatives. The Danaher Business System is a key differentiator. Key challenges include integrating acquisitions and managing economic cyclicality, but their market position and innovation efforts provide a stable outlook.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Danaher Corporation Investor Relations
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Danaher Corporation
Exchange NYSE | Headquaters Washington, DC, United States | ||
IPO Launch date 1979-01-05 | President, CEO & Director Mr. Rainer M. Blair | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 61000 | Website https://www.danaher.com |
Full time employees 61000 | Website https://www.danaher.com | ||
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a partnership with AstraZeneca PLC to develop and commercialize diagnostic tools and tests. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.